Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.

Clin Cancer Res. 2020 Jan 15;26(2):439-449. doi: 10.1158/1078-0432.CCR-19-1667. Epub 2019 Sep 23.


Engineering Multidimensional Evolutionary Forces to Combat Cancer.

McCoach CE, Bivona TG.

Cancer Discov. 2019 May;9(5):587-604. doi: 10.1158/2159-8290.CD-18-1196. Epub 2019 Apr 16. Review.


A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.

McCoach CE.

J Thorac Oncol. 2019 Jan;14(1):8-10. doi: 10.1016/j.jtho.2018.10.009. No abstract available.


Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM.

Clin Lung Cancer. 2019 Mar;20(2):e137-e141. doi: 10.1016/j.cllc.2018.11.003. Epub 2018 Nov 20. No abstract available.


Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG.

Cancer Res. 2019 Feb 1;79(3):546-556. doi: 10.1158/0008-5472.CAN-18-1492. Epub 2018 Dec 11.


Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.


The evolving understanding of immunoediting and the clinical impact of immune escape.

McCoach CE, Bivona TG.

J Thorac Dis. 2018 Mar;10(3):1248-1252. doi: 10.21037/jtd.2018.03.60. No abstract available.


Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC.

Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10.


Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.

McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le AT, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC.

Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29.


Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

McCoach CE, Blumenthal GM, Zhang L, Myers A, Tang S, Sridhara R, Keegan P, Pazdur R, Doebele RC, Kazandjian D.

Ann Oncol. 2019 Mar 1;30(3):492. doi: 10.1093/annonc/mdy045. No abstract available.


The importance of the initial response to cancer treatment in predicting longer overall survival.

McCoach CE, Doebele RC.

Expert Rev Clin Pharmacol. 2018 Feb;11(2):109-111. doi: 10.1080/17512433.2018.1419428. Epub 2017 Dec 26. No abstract available.


Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.


Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

McCoach CE, Blumenthal GM, Zhang L, Myers A, Tang S, Sridhara R, Keegan P, Pazdur R, Doebele RC, Kazandjian D.

Ann Oncol. 2017 Nov 1;28(11):2707-2714. doi: 10.1093/annonc/mdx414. Erratum in: Ann Oncol. 2019 Mar 1;30(3):492.


Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.

McCoach CE, Bivona TG, Blakely CM, Doebele RC.

Clin Lung Cancer. 2016 Sep;17(5):466-469. doi: 10.1016/j.cllc.2016.05.025. Epub 2016 Jun 8.


A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the Trial Registry.

McCoach CE, Berge EM, Lu X, BarĂ³n AE, Camidge DR.

J Thorac Oncol. 2016 Mar;11(3):407-13. doi: 10.1016/j.jtho.2015.10.024. Epub 2015 Dec 25.


Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer.

McCoach CE, Rogers JG, Dwyre DM, Jonas BA.

Cancer Treat Commun. 2015;4:15-18. No abstract available.


The minority report: targeting the rare oncogenes in NSCLC.

McCoach CE, Doebele RC.

Curr Treat Options Oncol. 2014 Dec;15(4):644-57. doi: 10.1007/s11864-014-0310-8. Review.


Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.

Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, Yeo KK, Anderson D, Amsterdam EA, Laird JR.

J Am Heart Assoc. 2014 Apr 10;3(2):e000697. doi: 10.1161/JAHA.113.000697.


Treatment paradigms in advanced non-small-cell lung cancer.

McCoach CE, Kelly K.

Clin Adv Hematol Oncol. 2013 Oct;11(10):629-39. Review.


Fungating mass as first presentation of advanced breast cancer.

McCoach CE, Aronowitz P.

J Gen Intern Med. 2014 Apr;29(4):685. doi: 10.1007/s11606-013-2600-4. Epub 2013 Sep 25. No abstract available.


Gender-related variation in the clinical presentation and outcomes of critical limb ischemia.

McCoach CE, Armstrong EJ, Singh S, Javed U, Anderson D, Yeo KK, Westin GG, Hedayati N, Amsterdam EA, Laird JR.

Vasc Med. 2013 Feb;18(1):19-26. doi: 10.1177/1358863X13475836.

Supplemental Content

Loading ...
Support Center